Healthcare professionals working in organisations that subscribe to ScriptSwitch may register to request access – please submit your details via the ‘register’ link at the top of this page.
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 12 October 2011 The European Medicines Agency (EMA) has announced a review of orlistat, to determine whether the very rare cases of liver injury associated with its use have […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 2 December 2010 A recent small study found that two thirds of adults in one GP practice who were taking orlistat for obesity continued to be prescribed the drug […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 04 March 2010 Obese, non-diabetic patients received one of four doses of liraglutide▼ subcutaneously once a day versus open-label orlistat orally three times a day in a European, phase […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The Drug Safety Update is an NHS Evidence accredited provider 19 February 2010 The MHRA and CHM have published the February edition of Drug Safety Update This edition includes […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 22 January 2010 The MHRA has announced that the licence for sibutramine has been suspended throughout Europe. This follows a review which considered the increased risk of non-fatal heart […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. 22 September 2009 The FDA is reviewing the safety information for Orlistat following reports of serious liver injury. However, no definite association between liver injury and orlistat has been […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. The MHRA has announced the Europe-wide suspension of the Marketing Authorisation for rimonabant▼ (Acomplia®) following recommendations from the EMEA’s Committee for Medicinal Products for Human Use (CMHP). The CMHP […]
NOTE – This is an archive post from the NPC and has not been updated since first publication. Therefore, some hyperlinks may no longer be working. NICE has published a Final Appraisal Determination (FAD) for rimonabant▼ for the treatment of overweight and obese patients. In the Appraisal Consultation Document, published in December 2007, the Appraisal […]